The average cost per enrollee per month was $110, or $1,320 per annum. 5 key findings →
Participants: 360 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In both databases, total healthcare resource utilization and costs increased with number of core features. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source
On average, ADRD diagnosis was not significantly associated with excess Medicare payments over the last 5 years of life. 5 key findings →
Participants: 4,899 Evidence: low
Full summary, score breakdown and related studies → Original source
Most PWD (67%) met criteria for another manifestation of serious illness (24% advanced medical condition, 44% ADL impairment). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Average adherence was 41%. Despite this, remote measures demonstrated excellent reliability (ICCs > 0.90 after 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Findingss: upport multidomain prevention strategies targeting clustered modifiable risks. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
We identified chemicals enriched for dementia pathways, suggesting broad classes of chemicals contribute to dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive decline is closely associated with biological aging and with interconnected processes, including chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Trisomy 21 (T21) gives rise to Down syndrome (DS), the most commonly occurring chromosomal abnormality in humans. 2 key findings →
Participants: 400 Evidence: low
Full summary, score breakdown and related studies → Original source
This study contributes to the healthcare field by demonstrating the potential of providing a fast, transparent, and affordable assessment system that is accessible to low-income populations and clinics with limited budget. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our new NfL ELISA showed a good analytical performance (inter-plate coefficient of variation (CV) < 13%), with no cross-reactivity with neurofilament medium and heavy (NfM and NfH). 5 key findings →
Participants: 97 Evidence: low
Full summary, score breakdown and related studies → Original source
Evidence supports an important role for beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD). 2 key findings →
Participants: 137 Evidence: moderate
Full summary, score breakdown and related studies → Original source
ApoE-4 was strongly associated with AD in this sample (allele frequency = 0.46 vs. 0.14 in controls, p < 0.000001). 5 key findings →
Participants: 679 Evidence: low
Full summary, score breakdown and related studies → Original source
An association between the 19q13.2 chromosomal region and Alzheimer's disease (AD) has been reported in AD families and for sporadic AD. 5 key findings →
Participants: 36 Evidence: low
Full summary, score breakdown and related studies → Original source
According to the network model of neurodegeneration, the spread of pathogenic proteins occurs selectively along connected brain regions. 2 key findings →
Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
Our cohort was composed of 59 cognitively normal participants and 10 cognitively impaired individuals. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuropathological studies have shown that the typical neurofibrillary pathology of hyperphosphorylated tau protein in Alzheimer’s disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. 5 key findings →
Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source
Hippocampal atrophy detected by volumetric MRI is a sensitive feature of early Alzheimer's disease (AD), but there are no studies evaluating hippocampal atrophy by MR volumetry in other dementing diseases. 2 key findings →
Participants: 113 Evidence: low
Full summary, score breakdown and related studies → Original source
48/100
Age and BMI were each associated with decreased brain volume. 3 key findings →
Participants: 114 Evidence: low
Full summary, score breakdown and related studies → Original source
N/A. ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD. 1 key finding →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
48/100
Given the importance of identifying dementia prodromes for future treatment efforts, we examined two methods of diagnosing mild cognitive impairment (MCI) and determined whether empirically-derived MCI subtypes of these diagnostic methods were consistent with one another as well as with conventional MCI subtypes (i.e., amnestic, non-amnestic, single-domain, multi-domain). 2 key findings →
Participants: 134 Evidence: low
Full summary, score breakdown and related studies → Original source
Despite the use of a common, reliable methodology for the assessment and diagnosis of major depressive episodes, the prevalence of major depression in Alzheimer's disease ranged widely from 22.5% to 54.4% across the recruitment sites. 5 key findings →
Participants: 243 Evidence: low
Full summary, score breakdown and related studies → Original source
To determine the impact of dementia on the family, we interviewed the primary care givers of 55 patients suffering from an irreversible dementia. 3 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
614 subjects were available for investigation at follow-up. 5 key findings →
Participants: 614 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), non-AD dementia, and Parkinson's disease (PD) are increasingly common in older adults, yet all risk factors for their onset are not fully understood. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →